Personal record-keeping and educational reference. 18+. The app does not recommend substances, doses or treatment, or determine whether a substance is safe, approved or appropriate for you. Consult a qualified healthcare professional about decisions involving your health.
‹ Library

Cagrilintide + GLP-1 Blend

Blend & StackResearch Use Only

Also known as: CagriSema-style Blend, Cagri + GLP-1

The 'CagriSema' approach in one vial — amylin plus GLP-1 for two-pathway appetite control.

Dosing quick reference

research reference
Starting dose
0.5 mg total once weekly (0.25 mg each)
Frequency
Once weekly
Typical range
0.25–2.4 mg of each, weekly
Cycle
16+ weeks of GLP-1-style escalation
Titration (step-up)
Each peptide: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, stepping every 4 weeks
Half-life
Varies by component
Route
Subcutaneous (research)
Common use
Metabolic and appetite-signaling research
Common vial sizes
10 mg total
Storage
Refrigerate reconstituted solution at 2-8 C; keep powder cold until reconstitution.
Stacking notes
Components: Cagrilintide (amylin analog), a GLP-1 receptor agonist (e.g. semaglutide).

Reported side effects

Nausea reported anecdotallyReduced appetiteGastrointestinal discomfort reported anecdotallyHuman data limited in this specific blend form
Regulatory note: GLP-1 receptor agonists such as semaglutide are approved prescription drugs in Canada and other jurisdictions; this blend contains a regulated pharmaceutical component.
Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.